Aug 19 (Reuters) - Canada's health regulator has approved Novo Nordisk's NOVOb.CO diabetes drug, Ozempic, for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease, the Danish drugmaker said on Tuesday.